Arrien Pharmaceuticals   Report issue

For profit Phase 1
Founded: Ansonia CT United States (2011)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2016
NCT03237832
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Arrien Pharmaceuticals

Active Ingredients

Drugs in Phase 1 Trials (1)

arn-6039 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Sclerosis (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1